Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Disease (CBD)

Inclusion Criteria:

Chronic Beryllium Disease (CBD):

1. History of Beryllium exposure

2. Positive blood and/or bronchoalveolar lavage (BAL) Beryllium Lymphocyte Proliferation
Tests (BeLPT)

3. Biopsy-proven pathologic changes consistent with CBD, specifically non-caseating
granulomas and/or mononuclear cell interstitial infiltrates.

Beryllium Sensitization:

1. History of Beryllium exposure

2. Two or more positive blood beryllium lymphocyte proliferation tests (BeLPT) or
positive bronchoalveolar lavage (BAL) BeLPT

3. Normal lung tissue (no histology suggestive of CBD).

Normal Controls:

1. No history of beryllium exposure

2. Former smokers or never smokers -

Exclusion Criteria:

Chronic Beryllium Disease:

1. Immunosuppressive therapy within the last three months

2. Current cigarette smoking or smoking within six months prior to the study

3. Positive lung washing or biopsy cultures for fungi, mycobacteria or other respiratory
pathogen consistent with an acute or chronic infection

4. Weight less than 110 lbs. (for venipuncture)

5. Pregnancy

6. Severe room air hypoxemia and or hypercapnia (precluding BAL), e.g., resting PaO2 <
45, PaCO2 > 45 mm Hg; (Denver altitude 5,280 feet)

7. Presence of another disease that may be expected to significantly affect patient
mortality and or the immune response (e.g., HIV, HCV, cancer, uncorrected bleeding
diathesis, acute hypercapnia with a resting PaCO2 above 45 mm Hg; serious cardiac
arrhythmia, recent myocardial infarction within 6 weeks)

8. Patient inability to participate in the study, such as inability to undergo
venipuncture and BAL procedures that form part of the inclusion/exclusion criteria or
part of the outcome measure

Beryllium Sensitization:

1. Known underlying systemic or lung disease;

2. Current cigarette smoking or smoking within six months prior to the study

3. Positive lung pathology consistent with CBD

4. Pregnancy

5. Weight less than 110 lbs. (for venipuncture)

6. Presence of another disease that may be expected to significantly affect patient
mortality and or the immune response (e.g., HIV, HCV, cancer, uncorrected bleeding
diathesis, serious cardiac arrhythmia; recent myocardial infarction within 6 weeks)

7. Patient inability to participate in the study, such as inability to undergo
venipuncture and BAL procedures that form part of the inclusion/exclusion criteria or
part of the outcome measure

Normal Controls:

1. History of beryllium exposure

2. Known underlying systemic or lung disease;

3. Immunosuppressive therapy or other medication for as systemic disease process in the
last 3 months;

4. Current smokers or smoking within 6 months of study

5. Pregnancy

6. Weight less than 110 lbs. (for venipuncture)

7. Inability to undergo BAL or venipuncture procedures -